Clinical Trial Software by Therapeutic Area
Every therapeutic area has unique challenges. Clincove provides purpose-built tools and workflows tailored to the specific demands of your research.
One platform. Every indication.
See how Clincove's unified dashboard adapts to every therapeutic area with configurable workflows, real-time metrics, and study-specific views.
Purpose-Built for Your Research
Explore how Clincove handles the specific requirements of each therapeutic area.
Oncology
Clincove provides purpose-built clinical trial management software for oncology research. Our platform supports Phase I-IV oncology trials with native adaptive design capabilities, integrated biomarker tracking, automated safety surveillance, and multi-site coordination across global regulatory jurisdictions.
Rare Disease
Clincove's clinical trial platform is designed for the unique constraints of rare disease research. With built-in tools for global patient recruitment, natural history data integration, decentralized trial capabilities, and regulatory pathway support for orphan drug designations, our platform helps sponsors run effective trials even with very small patient populations.
CNS & Neurology
Clincove supports the unique demands of CNS and neurology clinical trials. Our platform provides validated electronic clinical outcome assessment (eCOA) instruments, rater management and certification tracking, long-term data integrity controls for multi-year studies, and flexible consent models for patients with cognitive impairment.
Immunology & Inflammation
Clincove powers immunology and inflammation clinical trials with integrated biomarker dashboards, mobile-first patient-reported outcome collection, competitive enrollment intelligence, and global regulatory submission support for biologic and biosimilar pathways.
Cardiovascular
Clincove is built for the scale and complexity of cardiovascular clinical trials. Our platform supports large-scale outcome trials (CVOTs) with integrated endpoint adjudication, real-time cardiac safety monitoring, and pre-built regulatory packages for FDA and EMA cardiovascular submission requirements.
Vaccines & Infectious Disease
Clincove accelerates vaccine and infectious disease clinical trials with rapid site activation tools, mass-scale safety surveillance for large healthy volunteer populations, integrated central lab immunogenicity data, and rolling regulatory submission support for standard and emergency use authorization pathways.
One Platform. Every Therapeutic Area.
Unlike point solutions that force you to adapt your workflow, Clincove provides a unified clinical trial platform with therapeutic-area-specific configurations built in.
Unified Data Layer
eISF, eTMF, EDC, and eSource share one data model. No integration headaches, no data silos.
Built-in Compliance
21 CFR Part 11, GDPR, HIPAA, and ICH-GCP compliant out of the box. Audit-ready from day one.
Global Scale
Support for multi-region studies with local regulatory requirements, languages, and site configurations.
How Clincove Adapts to Complex Study Designs
Adaptive & Master Protocols
Modern clinical trials demand platforms that can adapt to increasingly complex study designs across therapeutic areas. Whether your protocol calls for adaptive designs with interim analyses, master protocols spanning multiple indications, or basket trials that require flexible stratification, Clincove provides the operational infrastructure to execute without custom development. Our platform maintains full CDISC compliance (CDASH, SDTM, ADaM) across all data capture and submission workflows.
Global Regulatory Compliance
Every study configured on Clincove is built to satisfy ICH-GCP guidelines and regulatory requirements from the FDA, EMA, and PMDA. From endpoint adjudication in cardiovascular outcome trials to validated eCOA instruments in CNS studies, the platform provides therapeutic-area-specific modules that integrate natively with core EDC, eISF, and eTMF capabilities. This eliminates the integration burden that plagues sponsors using fragmented vendor stacks.
Decentralized & Hybrid Trials
For sponsors running decentralized or hybrid trials, Clincove offers integrated ePRO/eCOA collection, remote site monitoring, and eConsent workflows that reduce patient burden while maintaining 21 CFR Part 11 compliance. Whether you are managing a 500-site cardiovascular outcome trial or a 20-patient rare disease natural history study, the platform scales to match your operational complexity without sacrificing data integrity or audit readiness.
Frequently Asked Questions
Common questions about Clincove's multi-therapeutic-area capabilities.
Yes. Clincove provides a unified platform with therapeutic-area-specific configurations for EDC forms, visit schedules, safety workflows, and regulatory templates. Whether you are running an oncology basket trial or a rare disease natural history study, the same core platform adapts to your protocol without custom development or separate system deployments.
Clincove includes validated electronic clinical outcome assessment (eCOA) instruments and patient-reported outcome (ePRO) modules for each therapeutic area. CNS trials get pre-built MMSE and ADAS-Cog scales, immunology trials get multilingual PRO questionnaires, and cardiovascular trials get MACE event capture forms — all with automated scoring, compliance monitoring, and regulatory-ready audit trails.
Every module in Clincove is built with 21 CFR Part 11 compliance, including electronic signatures, complete audit trails, role-based access controls, and validated system infrastructure. This applies across all therapeutic areas and study types, from small Phase I dose-escalation studies to large-scale Phase III cardiovascular outcome trials.
Clincove natively supports master protocols, basket trials, umbrella trials, and platform trials. The EDC and study management modules allow multiple sub-studies to share a common infrastructure while maintaining independent arms, endpoints, and interim analyses. Protocol amendments can be applied globally or to individual arms without costly EDC rebuilds.
